Prosensa Holding N.V. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (39)

View All

Latest Posts

About This Stock More About This Stock
Building Products Maker Azek Surges In Debut
Article By: The Fly
Sunday, June 14, 2020 2:18 PM EDT
After opening higher, building products maker Azek ended its first trading day up over 18%. The company raised about $765 million in the biggest initial public offering of the week.
In this article: RNA Also: BAC, GS, WFC, VXX, JEF, TREX, CS, LLY, COWN, SIVBQ, JPM, MS, EVR, RPRX, ADCT
Read
Shares Of Prosensa Surge 50% After Announcing It Will Be Acquired By Biomarin
Article By: Terry Chrisomalis
Monday, November 24, 2014 10:33 AM EDT
Biomarin is purchasing Prosensa for approximately $840 million.
In this article: BMRN, RNA, SRPT, RGLS
Read
Sarepta Hits Another Roadblock Prior To Eteplirsen New Drug Application
Article By: Jake King
Monday, October 27, 2014 5:32 PM EDT
On Monday morning, Sarepta Therapeutics (SRPT) held a teleconference concerning regulatory updates for Eteplirsen, the company's lead drug candidate for Duchenne Muscular Dystrophy.
In this article: RNA, SRPT
Read
ROTH Capital's Debjit Chattopadhyay: Marriage Of Diagnostics To New Therapies Breeds Biotech Winners
Article By: The Life Sciences Report
Wednesday, September 24, 2014 4:53 PM EDT
A medical researcher turned biotech analyst highlights several companies with unique diagnostic and therapeutic technologies.
In this article: BAX, CVD, DGX, NGNM, RHHBY, INCY, CTIC, RNA, SRPT
Read
Sarepta Tumbles On New Drug Data But Presents A Big Buying Opportunity
Article By: Terry Chrisomalis
Monday, July 14, 2014 3:25 PM EDT
Shares of Sarepta Therapeutics (SRPT) tumbled as much as 28% after it updated its phase 2b data from its Eteplirsen study. But the stock fell for the wrong reasons and should still be a strong buy. Here's why...
In this article: RNA, SRPT
Read
All Posts

Latest Tweets for $RNA

No tweets yet!

PARTNER HEADLINES